<DOC>
	<DOCNO>NCT01756027</DOCNO>
	<brief_summary>Up 12 subject enrol . Enrolled subject receive one two Ultherapy treatment cheek , depend assign study group . Follow-up visit occur 14 , 30 90 day post-treatment . Study image obtain pre-treatment , 30-60 min post-treatment , follow-up visit .</brief_summary>
	<brief_title>Feasibility Study : Ulthera System Treatment Rosacea</brief_title>
	<detailed_description>This study prospective , randomize , single-center clinical trial . The study conduct two Phases . In Phase I , subject assign one two treatment group . One study group receive one dual depth Ultherapy treatment region cheek , one study group receive two dual depth Ultherapy treatment region cheek 14 day apart . Average pain score obtain use Numeric Rating Scale follow region treatment depth treatment . In Phase II , base observation last follow-up visit Phase I ( 90 day treatment ) , subject give option receive treatment affect area ( ) protocol specify region , treat treatment depth show efficacy Phase I. Efficacy determine improvement Erythematotelangiectatic Rosacea treatment area versus control ( untreated area ) determine primary investigator assessment last follow-up visit Phase I .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<criteria>Male female , age 18 65 year . Subject good health . Clinical diagnosis Erythematotelangiectatic Rosacea . Understands accepts obligation undergo procedure area ( ) treat followup period . Willingness ability comply protocol requirement , include return followup visit abstain exclusionary procedure duration study . Absence physical psychological condition unacceptable investigator . Willingness ability provide write consent studyrequired photography adherence photography requirement . Willingness ability provide write informed consent HIPAA authorization prior performance studyrelated procedure . Subjects childbearing potential must negative urine pregnancy test result must lactate Visit 1 . Presence active systemic disease may affect wound healing . Prominent telangiectases area ( ) treat . History postinflammatory hyperpigmentation . Papulopustular Phymatous Rosacea . Severe solar elastosis . Significant scarring area ( ) treat . Open wound lesion area ( ) treat . Severe cystic acne area ( ) treat . Presence metal stent implant area ( ) treat . Inability understand protocol give inform consent . Microdermabrasion , prescription level glycolic acid treatment intend treatment area ( ) within six week prior study participation study . Marked asymmetry , ptosis , excessive dermatochalasis , deep dermal scarring , thick sebaceous skin area ( ) treat . History chronic drug alcohol abuse . History autoimmune disease . Concurrent therapy , investigator 's opinion , would interfere evaluation safety efficacy study device . Subjects anticipate need surgery overnight hospitalization study . Subjects , investigator 's opinion , history poor cooperation , noncompliance medical treatment , unreliability . Concurrent enrollment study involve use investigational device drug . Current smoker history smoking last five year . History follow cosmetic treatment area ( ) treat : 1 . Skin tighten procedure within past year ; 2 . Injectable filler type within past : 12 month Hyaluronic acid filler ( e.g. , Restylane ) 12 month Ca Hydroxyapatite filler ( e.g. , Radiesse ) 24 month PolyLLactic acid filler ( e.g. , Sculptra ) Ever permanent filler ( e.g. , Silicone , ArteFill ) 3 . Neurotoxins within past three month ; 4 . Ablative resurface laser treatment ; 5 . Nonablative , rejuvenative laser light treatment within past six month ; 6 . Surgical dermabrasion deep facial peel History use follow prescription medication : 1 . Accutane systemic retinoids within past six month ; 2 . Topical Retinoids within past two week ; 3 . Antiplatelet agent / Anticoagulants ( Coumadin , Heparin , Plavix ) ; 4 . Psychiatric drug investigator opinion would impair subject understand protocol requirement understand signing informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Rosacea</keyword>
	<keyword>Ulthera System</keyword>
	<keyword>Ultherapyâ„¢ Treatment</keyword>
	<keyword>Ulthera , Inc .</keyword>
	<keyword>Ultrasound treatment skin</keyword>
</DOC>